Severe long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in the vervet monkey (Cercopithecus aethiops sabaeus)

Neuroscience

Volumn 81, Issue 3, 1997, Pages 745-755

  Taylor, J R ^a   Elsworth, J D ^a   Roth, R H ^a   Sladek Jr, J R ^b   Redmond Jr, D E ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b University of the Health Sciences   (United States)

Author keywords

Behaviour; Monkey; MPTP; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; MONKEY; NEUROCHEMISTRY; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BEHAVIOR, ANIMAL; CERCOPITHECUS AETHIOPS; CHRONIC DISEASE; DISEASE PROGRESSION; MALE; MOVEMENT; PARKINSON DISEASE, SECONDARY; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 0031587263     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(97)00214-5     Document Type: Article

References (64)

1. Annett L. E., Rogers D. C. and Dunnett S. B. (1990) Unilateral 6-OHDA lesions in marmosets: a primate model for neural transplantation in Parkinson's disease. In Function and Dysfunction of the Basal Ganglia (eds Franks A. J., Ironside J. W., Mindham R. H. S., Smith R. J., Spokes E. G. S. and Winlow W.), pp. 181-197. Manchester University Press, Manchester.
2. Annett L. E., Rogers D. C., Hernandez T. D., Dunnett S. B. Behavioral analysis of unilateral monoamine depletion in the marmoset. Brain. 115:1992;825-856.
3. Bakay R. A., Barrow D. L., Fiandaca M. S., Iuvone P. M., Schiff A., Collins D. C. Biochemical and behavioral correction of MPTP parkinsonian like syndrome by fetal cell transplantation. Ann. N. Y. Acad. Sci. 495:1987;623-640.
4. Bankiewicz K. S., Oldfield E. H., Chiueh C. C., Doppman J. L., Jacobowitz D. M., Kopin I. J. Hemiparkinsonism in monkeys after unilateral internal carotid artery infusions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Life Sci. 39:1986;7-16.
5. Bankiewicz K. S., Plunkett R. J., Jacobowitz D. M., Porrino L., Di Porzio U., London W. T., Kopin I. J., Oldfield E. H. The effect of fetal mesencephalon implants on primate MPTP-induced parkinsonism. Histochemical and behavioral studies. J. Neurosurg. 72:1990;231-244.
6. Baulu J., Redmond D. E. Jr. Some sampling considerations in the quantitation of monkey behavior under field and captive conditions. Primates. 19:1978;391-399.
7. Burns R. S., Chiueh C. C., Markey S. P., Ebert M. H., Jacobowitz D. M., Kopin I. J. A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. natn. Acad. Sci. U.S.A. 80:1983;4546-4550.
8. Burns R. S., LeWitt P. A., Ebert M. H., Pakkenberg H., Kopin I. J. The clinical syndrome of striatal dopamine deficiency Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). New Engl J. Med. 312(22):1985;1418-1421.
9. Chiueh C. C., Burns R. S., Markey S. P., Jacobowitz D. M., Kopin I. J. III Primate model of Parkinsonism, Selective lesion of nigrostriatal neurons by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine produces an extrapyramidal syndrome in rhesus monkeys. Life Sci. 36:1985;213-218.
10. Chiueh C. C., Markey S. P., Burns R. S., Johannessen J. N., Jacobowitz D. M., Kopin I. J. Neurochemical and behavioral effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rat guinea pig and monkey. Psychopharmac. Bull. 20(3):1984;548-553.
11. Davis G. C., Williams A. C., Markey S. P., Ebert M. H., Caine E. D., Reichert C. M., Kopin I. J. Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiat. Res. 1:1979;249-254.
12. Di Paolo T., Bedard P., Daigle M., Boucher R. Long-term effects of MPTP on central and peripheral catecholamine and indoleamine concentrations in monkeys. Brain Res. 379:1986;286-293.
13. Doudet D., Gross C., Lebrun-Grandie P., Bioulac B. MPTP primate model of Parkinson's disease: a mechanographic and electromyographic study. Brain Res. 335:1985;194-199.
14. Doudet D., Gross C., Lebrun-Grandie P., Bioulac B. Effect of increasing regimens of levodopa on chronic MPTP-induced parkinsonism in monkeys: mechanographic and electromyographic data. Electromyo. clin. Neurophysiol. 26:1986;11-727.
15. Eidelberg E., Brooks B. A., Morgan W. W., Walden J. G., Kokemoor R. H. Variability and functional recovery in the N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of parkinsonism in monkeys. Neuroscience. 18(4):1986;817-822.
16. Ellis J. E., Byrd L. D., Bakay R. A. A method for quantitating motor deficits in a non-human primate following MPTP-induced parkinsonism and co-grafting. Expl Neurol. 115:1992;376-387.
17. Elsworth J. D., Deutch A. Y., Redmond D. E. Jr., Sladek J. R. Jr., Roth R. H. Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on catecholamines and metabolites in primate brain and CSF. Brain Res. 415:1987;293-299.
18. Elsworth J. D., Deutch A. Y., Redmond D. E. Jr., Sladek J. R. Jr., Roth R. H. Differential responsiveness to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in sub-regions of the primate substantia nigra and striatum. Life Sci. 40:1987;193-202.
19. Elsworth J. D., Deutch A. Y., Redmond D. E. Jr., Taylor J. R., Sladek J. R. Jr., Roth R. H. Symptomatic and asymptomatic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated primates: biochemical changes in striatal regions. Neuroscience. 33:1989;323-331.
20. Elsworth J. D., Deutch A. Y., Redmond D. E. Jr., Sladek J. R. Jr., Roth R. H. MPTP reduces dopamine and norepinephrine concentrations in the supplementary motor area and cingulate cortex of the primate. Neurosci. Lett. 114:1990;316-322.
21. Elsworth J. D., Lawrence M. S., Roth R. H., Taylor J. R., Mailman R. B., Nichols D. E., Lewis M. H., Redmond D. E. Jr. D1 and D2 dopamine receptors independently regulate spontaneous blink rate in the vervet monkey. J. Pharmac. exp. Ther. 259:1991;595-600.
22. Fahn S., Elton R. and members of the UPDRS Development Committee (1987) Unified Parkinson's disease rating scale. In Recent Advances in Parkinson's Disease (eds Fahn S., Marsden C. D., Goldstein M. and Calne C.), pp. 153-163. MacMillan, Florham Park, NJ.
23. Fine A., Hunt S. P., Oertel W. H., Nomoto M., Chong P. N., Bond A., Walters C., Temlett J. A., Annett L., Dunnett S., Jenner P., Marsden C. D. Transplantation of embryonic marmoset dopaminergic neurons to the corpus striatum of marmosets rendered parkinsonian by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Prog. Brain Res. 78:1988;479-490.
24. Gash D. M., Zhang Z., Ovadia A., Cass W. A., Yi A., Simmerman L.et al. Functional recovery in parkinsonian monkeys treated with GDNF. Nature. 380(6571):1996;252-255.
25. Guttman M., Fibiger H. C., Jakubovic A., Calne D. B. Intracarotid 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration, biochemical and behavioral observations in a primate model of hemiparkinsonism. J. Neurochem. 54:1990;1329-1334.
26. Geminiani G., Cesana B. M., Tamma F., Contri P., Pachetti C., Carella F.et al. Inter-rater reliability between neurologists in training of Parkinson's disease rating scales. Movement Disord. 6:1991;330-335.
27. Hantraye P., Varaset M., Peschanski M., Riche D., Cesaro P., Willer J. C., Maziere M. Stable parkinsonism syndrome and uneven loss of striatal dopamine fibers following chronic MPTP administration in baboons. Neuroscience. 53:1993;169-178.
28. Henderson L., Kennard C., Crawford T. J.et al. Scales for rating motor impairment in Parkinson's disease: studies of reliability and and convergent validity. J. Neurol. Neurosurg. Psychiat. 54:1991;18-24.
29. Jenner P. and Marsden C. D. (1986) The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease. J. neural Transm., Suppl. 20, 11-39.
30. Jenner P. and Marsden C. D. (1990) 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), an update on its relevance to the cause and treatment of Parkinson's disease. In Function and Dysfunction of the Basal Ganglia (eds Franks A. J., Ironside J. W., Mindham R. H. S., Smith R. J., Spokes E. G. S. and Winlow W.), pp. 140-160. Manchester University Press, Manchester.
31. Kennard C., Munro A. J., Park D. M. The reliability and clinical assessment of Parkinson's disease. J. Neurol. Neurosurg. Psychiat. 47:1984;322-323.
32. Langston J. W., Ballard P., Tetrud J. W., Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 219:1983;979-980.
33. Langston J. W., Forno L. S., Rebert C. S., Irwin I. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the squirrel monkey. Brain Res. 292:1984;390-394.
34. Mitchel I. J., Cross A. J., Sambrook M. A. and Crossman A. R. (1986) N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the monkey, Neurochemical pathology and regional brain metabolism. J. neural Transm. Suppl. 20, 41-46.
35. Martinez-Martin P. (1993) Rating scales in Parkinson's disease. In Parkinson's Disease and Movement Disorders (eds Jankovic J. and Tolosa E.), pp. 281-292. Williams and Williams Press, Baltimore, MD.
36. Nomoto M., Jenner P., Marsden C. D. Alterations in motor behavior produced by the isomers of 3-PPP in the MPTP-treated marmoset. Eur. J. Pharmac. 121:1986;123-128.
37. Ovadia A., Zhang Z., Gash D. M. Increased susceptibility to MPTP toxicity in middle-aged rhesus monkeys. Neurobiol. Aging. 16(6):1995;931-937.
38. Redmond D. E. Jr., Sladek J. R. Jr., Roth R. H., Collier T. J., Elsworth J. D., Deutch A. Y., Haber S. N. Fetal neuronal grafts in monkeys given methylphenyltetra-hydropyridine. Lancet. 8490:1986;1125-1127.
39. Redmond D. E. Jr., Smith E. O., Roth R. H., Elsworth J. D., Taylor J. R., Sladek J. R. Jr., Innis R. B., Seibyl J. P., Hoffer P. B. SPECT studies with β-CIT identify dopamine grafts. Neurosci. Abstr. 20:1994;1464.
40. Rose S., Nomoto M., Jenner P., Marsden C. D. Transient depletion of nucleus accumbens dopamine content may contribute to inital akinesia induced by MPTP in common marmosets. Biochem. Pharmac. 38:1989;3677-3681.
41. Rose S., Nomoto M., Kelly E., Kilpatrick G., Jenner P., Marsden C. D. Increased caudate dopamine turnover may contribute to the recovery of motor function in marmosets treated with the dopaminergic neurotoxin MPTP. Neurosci. Lett. 101:1989;305-310.
42. Rothblat D. S., Schneider J. S. Repeated exposure to MPTP does not produce a permanent movement disorder in cats recovered from MPTP-induced parkinsonism. Neurodegeneration. 4:1995;87-92.
43. Schneider J., Kovelowski C. J. Chronic exposure to low doses of MPTP. I. Cognitive deficits in motor asymptomatic monkeys. Brain Res. 544:1990;297-302.
44. Schneider J., Rothblat D. S., DiStefano L. Functional recovery from experimental parkinsonism in cats is accompanied by partial recovery of extracellular but not tissue levels of dopamine in the dorsal lateral caudate nucleus. Neurodegeneration. 2:1993;209-212.
45. Schneider J. S., Unguez G., Yuwiler A., Berg S. C., Markham C. H. Deficits in operant behaviour in monkeys treated with N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Brain. 111:1988;1265-1285.
46. Schneider J. S., Yuwiler A., Markham C. H. Production of a Parkinson-like syndrome in cat with N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): behavior, histology and biochemistry. Expl Neurol. 91:1986;293-307.
47. Schneider J. S., Yuwiler A., Markham C. H. Selective loss of subpopulations of ventral mesencephalic dopamine neurons in the monkey following exposure to MPTP. Brain Res. 411:1987;144-150.
48. Schultz W., Studer A., Jonsson G., Sundstrom E., Mefford I. Deficits in behavioral initiation and execution processes in monkeys with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism. Neurosci. Lett. 59:1985;225-232.
49. Smith R. D., Zhang Z., Kurlan R., McDermott M., Gash D. M. Developing a stable bilateral model of parkinsonism in the rhesus monkey. Neuroscience. 52:1993;7-16.
50. Stern Y., Langston W. Intellectual changes in patients with MPTP-induced parkinsonism. Neurology. 35:1985;1506-1509.
51. Taylor J. R., Elsworth J. D., Roth R. H., Collier T. J., Sladek J. R. Jr., Redmond D. E. Jr. Improvements in MPTP-induced object retrieval deficits and behavioral deficits after fetal nigral grafting in monkeys. Prog. Brain Res. 82:1990;543-559.
52. Taylor J. R., Elsworth J. D., Roth R. H., Sladek J. R. Jr., Redmond D. E. Jr. Cognitive and motor deficits in the acquisition of an object retrieval/detour task in MPTP-treated monkeys. Brain. 113(3):1990;617-637.
53. Taylor J. R., Roth R. H., Sladek J. R. Jr., Redmond D. E. Jr. Cognitive and motor deficits in the performance of an object retrieval task with barrier/detour in monkeys treated with MPTP. Long-term performance and effect of transparency of the barrier. Behav. Neurosci. 104(4):1990;564-576.
54. Taylor J. R., Elsworth J. D., Roth R. H., Sladek J. R. Jr., Collier T. J., Redmond D. E. Jr. Grafting of fetal substantia nigra to striatum reverses behavioral deficits induced by MPTP in primates, a comparison with other types of grafts as controls. Expl Brain Res. 85:1991;335-348.
55. Taylor J. R., Lawrence M. S., Redmond D. E. Jr., Elsworth J. D., Roth R. H., Nichols D. E., Mailman R. B. Dihydrexidine, a full D1 agonist, reduces MPTP-induced parkinsonism in African green monkeys. Eur. J. Pharmac. 199(III):1991;387-388.
56. Taylor J. R., Elsworth J. D., Roth R. H., Sladek J. R. Jr and Redmond D. E. Jr (1994) Behavioral effects of MPTP administration in the vervet monkey: A primate model of Parkinson's disease. In Toxin-Induced Models of Neurological Disorders (eds Woodruff M. L. and Nonneman A. J.), pp. 139-174. Plenum Press, New York.
57. Taylor J. R., Elsworth J. D., Sladek J. R. Jr., Collier T. J., Roth R. H., Redmond D. E. Jr. Sham surgery does not ameliorate MPTP-induced behavioral deficits in monkeys. Cell Transplant. 4:1995;13-26.
58. Taylor J. R., Elsworth J. D., Lawrence M. S., Collier T. J., Sladek J. R. Jr, Roth R. H. and Redmond D. E. Jr (1996) Spontaneous eye blink rates correlate with MPTP-induced dopamine reductions in selected areas of the caudate nucleus in parkinsonian monkeys: evidence for blink rate as a measure of central dopamine function. Neurology (submitted).
59. Teravainen H. and Calne D. (1980) Quantitative assessment of parkinsonian deficits. In Parkinson's Disease; Current Progress, Problems and Management (eds Rinne U. K., Klinger M. and Stamm G.), pp. 145-164. Elsevier, Amsterdam.
60. Tetrud J. W., Langston J. W., Redmond D. E. Jr., Roth R. H., Sladek J. R. Jr., Angel R. W. MPTP-induced tremor in human and non-human primates. Neurology. 36(Suppl 1):1986;308.
61. U.S. Public Health Service (1985) Guide for the Care and Use of Animals, Washington, DC: U.S. Government Printing Office.
62. Vingerhoets F. J. G., Snow B. J., Tetrud J. W., Langston J. W., Schulzer M., Calne D. B. Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions. Ann. Neurol. 36:1994;765-770.
63. Winer, B. J. (1974) Statistical Principles in Experimental Design (2nd edn). McGraw Hill, New York.
64. Zigmond M. J., Stricker E. M. Animal models of parkinsonism using selective neurotoxins: clinical and basic implications. Int. Rev. Neurobiol. 31:1989;1-79.